

## Literatur

### Akute Pankreatitis

- Aggarwal A, Manrai M, Kochhar R: Fluid resuscitation in acute pancreatitis; *World J Gastroenterol* 2014; 20(48): 18092-103
- Balthazar EJ, Freeny PC, VanSonnenberg E: Imaging and Intervention in Acute Pancreatitis; *Radiology* 1994; 193: 297-306
- Balthazar EJ: Acute pancreatitis: assessment of severity with clinical and CT evaluation; *Radiology* 2002; 223(3): 603-13
- Banks PA, Bollen TL, Dervenis C et al: Acute Pancreatitis Classification Working Group: Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus; *Gut* 2013; 62: 102-11
- Bassi C, Larvin M, Villatoro E: Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis; *Cochrane Database Syst Rev* 2003; 4: CD002941
- Beger HG, Rau B, Mayer J et al.: Natural course of acute pancreatitis; *World J Surg* 1997; 21: 130-5
- Bhasin DK, Rana SS, Rawal P.: Endoscopic retrograde pancreatography in pancreatic trauma: need to break the mental barrier; *J Gastroenterol Hepatol* 2009; 24(5): 720-8
- Bradley EL 3rd, Allen K: A prospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis; *Am J Surg* 1991; 161: 19-24
- Bradley EL III: A Clinically Based Classification System for Acute Pancreatitis; *Arch Surg* 1993; 128: 586-90
- Brown A, Orav J, Banks PA: Hemoconcentration is an early marker for organ failure and necrotizing pancreatitis; *Pancreas* 2000; 20: 367-72
- Büchler M, Malfertheiner P, Friess H et al.: The penetration of antibiotics into human pancreas; *Infection* 1989; 17: 20-5
- De la Iglesia-Garcia D, Huang W, Szatmary P et al.: Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis; *Gut* 2017; 66(8): 1354-5
- Dellinger EP, Tellado JM, Soto NE: Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study; *Ann Surg* 2007; 245: 674-83
- Di MY, Liu H, Yang ZY et al.: Prediction models of mortality in acute pancreatitis in adults: A systematic Review; *Ann Intern Med* 2016; 165(7): 482-90
- Dellinger EP, Forsmark CE, Layer P, et al. on behalf of the Pancreatitis Acrosss Nations Clinical Research an Education Alliance (PANCREA): Determinant-based classification of acute pancreatitis severity; *Ann Surg* 2012; 256: 875-80

- Golub R, Siddiqi F, Pohl D: Role of antibiotics in acute pancreatitis: A metaanalysis; J Gastrointest Surg 1998; 2: 496-503
- Götzinger P, Sautner T, Kriwanek S: Surgical Treatment for Severe Acute Pancreatitis: Extent and Surgical Control of Necrosis Determine Outcome; World J Surg 2002; 26(4): 474-8
- Hagenmüller F, Keuchel M: Akute Pankreatitis: Die früh-elektive endoskopische Intervention; Chirurg 2000; 71: 265-8
- Himel HS: Role of endoscopic retrograde cholangiopancreatography in early acute biliary pancreatitis; Surg Endosc 1999; 13: 541
- Isenmann R, Buchler M, Uhl W et al.: Pancreatic necrosis: an early finding in severe acute pancreatitis; Pancreas 1993; 8: 358-61
- Isenmann R, Runzi M, Kron M - German Antibiotics in Severe Acute Pancreatitis Study Group: Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial; Gastroenterology 2004; 126: 997-1004
- Janisch NH, Gardner TB: Advances in Management of Acute Pancreatitis; Gastroenterol Clin North Am 2016; 45(1): 1-8
- Karimgani I, Porter KA, Langevin RE et al.: Prognostic factors in sterile pancreatic necrosis; Gastroenterology 1992; 103: 1636-40
- Koch K, Drewelow B, Liebe S, Reding R, Riethling AK: Pancreatic penetration of antibiotics; Chirurg 1991; 62: 317-22
- Kramer KM, Levy H: Prophylactic antibiotics for severe acute pancreatitis: the beginning of an era; Pharmacotherapy 1999; 19: 592-602
- Lobo DN, Memon MA, Allison SP, Rowlands BJ: Evolution of nutritional support in acute pancreatitis; Br J Surg 2000; 87: 695-707
- Macari M, Finn ME, Bennett GL et al.: Differentiating pancreatic cystic neoplasms from pancreatic pseudocysts at MR imaging: value of perceived internal debris; Radiology 2009; 251(1): 77-84
- Mier J, Leon EL, Castillo A et al.: Early versus late necrosectomy in severe necrotizing pancreatitis; Am J Surg 1997; 173: 71-5
- Neoptolemos JP, Carr-Locke DL, London NJ et al.: Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gallstones; Lancet 1988; 2(8618): 979-83
- Nikfarjam M, Wilson JS, Smith RC et al.: Diagnosis and management of pancreatic exocrine insufficiency; Med J Aust 2017; 207(4): 161-5
- Oleynikov D, Cook C, Sellers B, Mone M, Barton R: Decreased mortality from necrotizing pancreatitis; Am J Surg 1998; 176: 648-53

- Papachristou G, Muddana V, Yadav D et al.: Comparison of BISAP, Ranson's, APACHE-II, and CTSI Scores in Predicting Organ Failure, Complications, and Mortality in Acute Pancreatitis; *Am J Gastroenterol* 2010; 105: 435–41
- Rosenberg A, Steensma EA, Napolitano LM: Necrotizing pancreatitis. New definitions and a new era in surgical management; *Surg Infect* 2015; 16: 1-13
- Schein M, Ivatury R: Intra-abdominal hypertension and the abdominal compartment syndrome; *Br J Surg* 1998; 85: 1027-8
- Singer M, Deutschman CS, Seymour CW et al.: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3); *JAMA* 2016; 315(8): 801-10
- Stimac D, Miletić D, Radić M et al.: The role of nonenhanced magnetic resonance imaging in the early assessment of acute pancreatitis; *Am J Gastroenterol* 2007; 102(5): 997-1004
- Struyvenberg MR, Martin CR, Freedman D: Practical guide to exocrine pancreatic insufficiency – Breaking the myths; *BMC Medicine* 2017; 15: 29
- Thomas S, Kayhan A, Lakadamyali H, Oto A: Diffusion MRI of acute pancreatitis and comparison with normal individuals using ADC values; *Emerg Radiol* 2012; 19(1): 5-9
- Uhl W, Buchler M, Malfertheiner P, Isenmann R: Pancreatic necrosis develops within four days after the acute attack; *Gastroenterology* 1991; 100: 123A
- [Van Brunschot S](#), [van Grinsven J](#), [Voermans RP](#) et al.: Transluminal endoscopic step-up approach versus minimally invasive surgical step-up approach in patients with infected necrotising pancreatitis (TENSION trial): design and rationale of a randomised controlled multicenter trial; *BMC Gastroenterol* 2013; 13: 161
- Van Santvoort HC, Besselink MG, Bakker OJ et al.: A step-up approach or open necrosectomy for necrotizing pancreatitis; *N Engl J Med* 2010; 362(16): 1491-502
- Watanabe S.: Acute pancreatitis: overview of medical aspects; *Pancreas* 1998; 16: 307-11
- Zaheer A, Singh VK, Qureshi RO et al.: The revised Atlanta classification for acute pancreatitis: updates in imaging terminology and guidelines; *Abdom Imaging* 2013; 38(1): 125-36

## **Chronische Pankreatitis – Bildgebende Verfahren**

- Anaizi A, Hart PA, Conwell DL: Diagnosing Chronic Pancreatitis; *Dig Dis Sci* 2017; 62(7): 1713-20
- Calvo MM, Bujanda L, Calderón A et al.: Comparison between magnetic resonance cholangiopancreatography and ERCP for evaluation of the pancreatic duct; *Am J Gastroenterol* 2002; 97(2): 347-53
- Lowenfels AB, Maisonneuve P, Cavallini G et al.: Pancreatitis and the risk of pancreatic cancer - International Pancreatitis Study Group; *N Engl J Med* 1993; 328(20): 1433-7

- Sanyal R, Stevens T, Novak E et al.: Secretin-enhanced MRCP: review of technique and application with proposal for quantification of exocrine function; *AJR Am J Roentgenol* 2012; 198(1): 124-32
- Sugiyama M, Haradome H, Atomi Y: Magnetic resonance imaging for diagnosing chronic pancreatitis; *J Gastroenterol* 2007; 42 Suppl 17: 108-12
- Tamura R, Ishibashi T, Takahashi S: Chronic pancreatitis: MRCP versus ERCP for quantitative caliber measurement and qualitative evaluation; *Radiology* 2006; 238(3): 920-8

## **Chronische Pankreatitis – Interventionelle Therapie**

- Barthet M, JP Bernard, Duval JL et al.: Biliary stenting in benign biliary stenosis complicating chronic calcifying pancreatitis; *Endoscopy* 1994; 26(7): 569-572
- Catalano MF, Linder JD, George S et al.: Treatment of symptomatic distal common bile duct stenosis secondary to chronic pancreatitis: comparison of single vs. multiple simultaneous stents; *Gastrointest Endosc* 2004; 60(6): 945-52
- Cahen DL, Gouma DJ, Nio Y et al.: Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis; *N Engl J Med* 2007; 356(7): 676-84
- Coté GA, Slivka A, Tarnasky P et al.: Effect of Covered Metallic Stents Compared With Plastic Stents on Benign Biliary Stricture Resolution: A Randomized Clinical Trial; *JAMA* 2016; 315(12): 1250-7
- Devière J, Nageshwar Reddy D, Püspök A et al.: Successful management of benign biliary strictures with fully covered self-expanding metal stents; *Gastroenterology* 2014; 147(2): 385-95
- Dite P, Ruzicka M, Zboril V, Novotny I: A prospective, randomized trial comparing endoscopic and surgical therapy for chronic pancreatitis; *Endoscopy* 2003; 35(7): 553-8
- Haapamäki C, Kylänpää L, Udd M et al.: Randomized multicenter study of multiple plastic stents vs. covered self-expandable metallic stent in the treatment of biliary stricture in chronic pancreatitis; *Endoscopy* 2015; 47(7): 605-10
- Jacobson BC, Baron TH, Adler DG et al.: ASGE guideline: The role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas; *Gastrointest Endosc* 2005; 61(3): 363-70
- Kahl S, Zimmermann S, Genz I et al.: Risk factors for failure of endoscopic stenting of biliary strictures in chronic pancreatitis: a prospective follow-up study; *Am J Gastroenterol* 2003; 98(11): 2448-53
- Mangiavillano B, Pagano N, Baron TH et al.: Biliary and pancreatic stenting: Devices and insertion techniques in therapeutic endoscopic retrograde cholangiopancreatography and endoscopic ultrasonography; *World J Gastrointest Endosc* 2016; 8(3): 143-56
- Pozsar J, Sahin P, Laszlo F et al.: Medium-term results of endoscopic treatment of common bile duct strictures in chronic calcifying pancreatitis with increasing numbers of stents; *J Clin Gastroenterol* 2004; 38(2): 118-23
- Rösch T, Dittler HJ: Routine use of transrectal ultrasound rectal carcinoma: results of a prospective multicenter study; *Endoscopy* 2002; 34: 385–90

## **Chronische Pankreatitis – Langzeitüberleben**

- Riediger H, Makowiec F, Fischer E et al.: Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection; *Journal of Gastrointestinal Surgery* 2006; 10(8): 1106–15

## **Chronische Pankreatitis – Schmerztherapie**

- Drewes AM, Bouwense SAW, Campbell CM et al.: Guidelines for the understanding and management of pain in chronic pancreatitis; *Pancreatology* 2017; doi: 10.1016/j.pan.2017.07.006 (Epub ahead of print)
- Häuser W, Bock F, Engeser P et al.: Empfehlungen der aktualisierten Leitlinie LONTS (Long-term opioid therapy for chronic noncancer pain); *Schmerz* 2015; 29: 109-30

## **Chronische Pankreatitis – Guidelines**

- Lühr JM, Dominguez-Munoz E, Rosendahl J et al.: United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU); *United European Gastroenterol J* 2017; 5(2): 153-99

## **Zystische Tumore des Pankreas – Bildgebende Verfahren**

- Morana G, Guarise A: Cystic tumors of the pancreas; *Cancer Imaging* 2006; 6: 60-71
- Procacci C, Biasutti C, Carbognin G et al.: Characterization of cystic tumors of the pancreas: CT accuracy; *J Comput Assist Tomogr* 1999; 23: 906-12
- Procacci C, Megibow AJ, Carbognin G et al.: Intraductal papillary mucinous tumor of the pancreas: a pictorial essay; *Radiographics* 1999; 19: 1447-63
- Sahani DV, Kadavigere R, Saokar A et al.: Cystic pancreatic lesions: a simple imaging-based classification system for guiding management; *Radiographics* 2005; 25: 1471-84
- Schima W, Ba-Ssalamah A, Plank C et al.: Pancreas Part II: Tumors; *Radiologe* 2006; 46: 421-437
- Tseng JF, Warshaw AL, Sahani DV et al.: Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment; *Ann Surg* 2005; 242: 413-9; discussion 419-21

## **Zystische Tumore des Pankreas – Chirurgie**

- Adsay V, Mino-Kenudson M, Furukawa T et al.: Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of

Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting; *Ann Surg* 2016; 263(1): 162-77

- Alexandrescu DT, O'Boyle K, Feliz A et al.: Metastatic solid-pseudopapillary tumour of the pancreas: clinico-biological correlates and management; *Clin Oncol (R Coll Radiol)* 2005; 17(5): 358-63
- Andriulli A, Loperfido S, Napolitano G et al.: Incidence Rates of Post-ERCP Complications: A Systematic Survey of Prospective Studies; *American Journal of Gastroenterology* 2007; 102: 1781-8
- Delcore R, Thomas JH, Forster J, Hermreck AS: Characteristics of cystic neoplasms of the pancreas and results of aggressive surgical treatment; *Am J Surg* 1992; 164(5): 437-41; discussion 441-32
- Fernandez-del Castillo C, Warshaw AL: Cystic tumors of the pancreas; *Surg Clin North Am* 1995; 75(5): 1001-16
- Iacono C, Bortolasi L, Serio G: Is there a place for central pancreatectomy in pancreatic surgery? *J Gastrointest Surg* 1998; 2(6): 509-16; discussion 516-7
- Kallen ME, Naini BV: Intraductal Oncolytic Papillary Neoplasms of the Pancreas; *Arch Pathol Lab Med* 2016; 140(9): 992-6
- Kimura W, Fuse A, Hirai I: Spleen-preserving distal pancreatectomy with preservation of the splenic artery and vein for intraductal papillary-mucinous tumor (IPMT): three interesting cases; *Hepatogastroenterology* 2003; 50(54): 2242-5
- Kim SH, Lee JM, Lee ES et al.: Intraductal Papillary Mucinous Neoplasms of the Pancreas: Evaluation of Malignant Potential and Surgical Resectability by Using MR Imaging with MR Cholangiography; *Radiology* 2015; 274(3): 723-33
- Kosmahl M, Pauser U, Anlauf M et al.: Cystic pancreas tumors and their classification: features old and new; *Pathologie* 2005; 26(1): 22-30
- Larsen A, Kwon RS: Natural History of Pancreatic Cysts; *Dig Dis Sci* 2017; 62(7): 1770-7
- Le Borgne J: Cystic tumours of the pancreas; *Br J Surg* 1998; 85(5): 577-9
- Matsumoto T, Aramaki M, Yada K et al.: Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas; *J Clin Gastroenterol* 2003; 36(3): 261-5
- Pyke CM, van Heerden JA, Colby TV et al.: The spectrum of serous cystadenoma of the pancreas. Clinical, pathologic, and surgical aspects; *Ann Surg* 1992; 215(2): 132-9
- Sakorafas GH, Sarr MG. Cystic neoplasms of the pancreas; what a clinician should know; *Cancer Treat Rev* 2005; 31(7): 507-35
- Sarr MG, Carpenter HA, Prabhakar LP et al.: Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? *Ann Surg* 2000; 231(2): 205-12
- Sarr MG, Kendrick ML, Nagorney DM et al.: Cystic neoplasms of the pancreas: benign to malignant epithelial neoplasms; *Surg Clin North Am* 2001; 81(3): 497-509

- Sarr MG, Murr M, Smyrk TC: Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions; J Gastrointest Surg 2003; 7(3): 417-28
- Warshaw AL, Compton CC, Lewandrowski K et al.: Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients; Ann Surg 1990; 212(4): 432-43; discussion 444

## **Zystische Tumore des Pankreas – Guidelines**

- Farrell JJ: Pancreatic Cysts and Guidelines; Dig Dis Sci 2017; 62(7): 1827-39
- Han DH, Lee H, Park JY et al.: Validation of international consensus guideline 2012 for intraductal papillary mucinous neoplasm of pancreas; Ann Surg Treat Res 2016; 90(3): 124-30
- Tanaka M, Fernandez-del Castillo C, Adsay V et al.: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas; Pancreatology 2012; 12: 183-97
- Tanaka M, Chari S, Adsay V: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas; Pancreatology 2006; 6(1-2): 17-32

## **Pankreaskarzinom – Bildgebende Verfahren**

- Bipat S, Phoa SSKS, van Delden OM et al.: Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic carcinoma; J Comput Assist Tomogr 2005; 29: 438–45
- Bronstein YL, Loyer EM, Kaur H et al.: Detection of small pancreatic tumors with multiphasic helical CT; Am J Roentgenol 2004; 182: 619–23
- Grenacher L, Klauss M, Dukic L et al.: Hochauflösende Bildgebung beim Pankreaskarzinom: Prospektiver Vergleich von MRT und 4-Zeilen-Spiral-CT; Fortschr Röntgenstr 2004; 176: 1624-33
- Irie H, Honda H, Kaneko K et al.: Comparison of helical CT and MR imaging in detecting and staging small pancreatic adenocarcinoma; Abdom Imaging 1997; 22: 429-33
- Koelblinger C, Ba-Ssalamah A, Goetzinger P et al: Gadobenate dimeglumineenhanced 3.0-T MR imaging versus multiphasic 64-detector row CT: prospective evaluation in patients suspected of having pancreatic cancer; Radiology 2011; 259(3): 57-66
- Legmann P, Vignaux O, Dousset B et al.: Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography; Am J Roentgenol 1998; 170: 1315-22
- Mallery JS, Centeno BA, Hahn PF et al.: Pancreatic tissue sampling guided by EUS, CT/US, and surgery: a comparison of sensitivity and specificity; Gastrointest Endoscopy 2002; 56: 218–24
- Schima W, Ba-Ssalamah A, Kölblinger C et al.: Pancreatic adenocarcinoma; EurRadiol 2007; 17: 638–49

- Schima W, Függer R, Schober E et al.: Diagnosis and staging of pancreatic cancer: comparison of mangafodipir-enhanced MRI and contrast-enhanced helical hydro-CT; *Am J Roentgenol* 2002; 179: 717-24

## **Pankreaskarzinom – Chirurgie**

- Alexakis N, Halloran C, Raraty M et al.: Current standards of surgery for pancreatic cancer; *Br J Surg* 2004; 91(11): 1410-27
- Bockhorn M, Uzunoglu FG, Adham M et al.: Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS); *Surgery* 2014; 155(6): 977-88
- Buchler MW, Wagner M, Schmied BM et al.: Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy; *Arch Surg* 2003; 138(12): 1310-4; discussion 1315
- Carpelan-Holmstrom M, Nordling S, Pukkala E et al.: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry; *Gut* 2005; 54(3): 385-7
- Delpero JR, Boher JM, Sauvanet A. et al: Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Francaise de Chirurgie; *Ann Surg Oncol* 2015; 22: 1874-83
- Diener MK, Knaebel HP, Heukaufers C et al.: A systematic review and metaanalysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma; *Ann Surg* 2007; 245(2): 187-200
- Friess H, Kleeff J, Kulli C et al.: The impact of different types of surgery in pancreatic cancer; *Eur J Surg Oncol* 1999; 25(2): 124-31
- Gangl O, Sahara K, Kornprat P et al.: Preparing for prospective clinical trials: A national initiative of an excellence registry for consecutive pancreatic cancer resections; *World Journal of Surgery* 2014; 38: 456-62
- Gudjonsson B: Cancer of the pancreas. 50 years of surgery; *Cancer* 1987; 60(9): 2284-303
- Hackert T., Sachsenmaier M., Hinz U. et al: Locally advanced pancreatic cancer: Neoadjuvant therapy with Folfirinox results in Resectability in 60 % of the Patients; *Annals of Surgery* 2016; 264: 457-63
- Hartel M, Wente MN, Hinz U et al.: Effect of antecolic reconstruction on delayed gastric emptying after the pylorus-preserving Whipple procedure; *Arch Surg* 2005; 140(11): 1094-9
- Kleeff J, Reiser C, Hinz U et al.: Surgery for recurrent pancreatic ductal adenocarcinoma; *Ann Surg* 2007; 245(4): 566-72
- Park YC, Kim SW, Jang JY et al.: Factors influencing delayed gastric emptying after pylorus-preserving pancreatoduodenectomy; *J Am Coll Surg* 2003; 196(6): 859-65



- Partelli S, Cirocchi R, Randolph J et al.: A systematic review and meta-analysis of spleen-preserving distal pancreatectomy with preservation or ligation of the splenic artery and vein; *Surgeon* 2016; 14(2): 109-18
- Pedrazzoli S, DiCarlo V, Dionigi R et al.: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study - Lymphadenectomy Study Group; *Ann Surg* 1998; 228(4): 508-17
- Pedrazzoli S, Pasquali C and Sperti C: Role of surgery in the treatment of biliopancreatic cancer: the European experience; *Semin Oncol* 2002; 29(6 Suppl 20): 23-30
- Schafer M, Mullhaupt B and Clavien PA: Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis; *Ann Surg* 2002; 236(2): 137-48
- Stojadinovic A, Brooks A, Hoos A et al.: An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma; *J Am Coll Surg* 2003; 196(6): 954-64
- Strobel O, Hank T, Hinz U et al.: Pancreatic Cancer Surgery: The New R-status Counts; *Ann Surg* 2017; 265(3): 565-73
- Tani M, Terasawa H, Kawai M et al.: Improvement of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy: results of a prospective, randomized, controlled trial; *Ann Surg* 2006; 243(3): 316-20
- Tarantino I, Warschkow R, Hackert T, et al.: Staging of pancreatic cancer based on the number of positive lymph nodes; *Br J Surg* 2017; 104(5): 608-18
- Wagner M, Redaelli C, Lietz M et al.: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma; *Br J Surg* 2004; 91(5): 586-94
- White RR, Shah AS and Tyler DS: Pancreatic cancer since Halsted: how far have we come and where are we going?; *Ann Surg* 2003; 238(6 Suppl): S132-44; discussion S145-7
- Yeo CJ, Cameron JL, Sohn TA et al.: Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome; *Ann Surg* 1999; 229(5): 613-22; discussion 622-4
- Z'Graggen K, Uhl W, Friess H and Buchler MW: How to do a safe pancreatic anastomosis; *J Hepatobiliary Pancreat Surg* 2002; 9(6): 733-7

## **Pankreaskarzinom – Adjuvante Chemotherapie**

- Chua YJ and Cunningham D: Adjuvant treatment for resectable pancreatic cancer; *J Clin Oncol* 2005; 23(20): 4532-7
- Corsini MM, Miller RC, Haddock MG et al Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005) *J. Clin. Oncol* 2008; 26: 3511-16

- Hazel JJ, Thirlwell MP, Huggins M et al: Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial *Journal of the Canadian Association of Radiologists* 1981 (<http://europepmc.org/abstract/MED/7028759>)
- Herman JM, Swartz MJ, Hsu CC et al: Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital; *J Clin Oncol* 2008; 26: 3503-10
- Kalser MH, Ellenberg SS: Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection; *Arch Surg* 1985; 120(8): 899-903
- Klinkenbijnl JH, Jeekel J, Sahnoud T et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. *Ann Surg.* 1999; 230(6): 776
- Koshy MC, Landry JC, Cavanaugh SX et al.: A challenge to the therapeutic nihilism of ESPAC-1; *Int J Radiat Oncol Biol Phys* 2005; 61(4): 965-6
- Neoptolemos JP, Dunn JA, Stocken DD et al: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial; *Lancet* 2001; 358(9293): 1576-85
- Neoptolemos JP, Stocken DD, Friess H et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer; *N Engl J Med* 2004; 350(12): 1200-10
- Neoptolemos JP, Palmer DH, Ghaneh P et al.: Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial; *Lancet* 2017; 389(10073): 1011-24
- Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, Zuelke C, Fahlke J, Langrehr J, Oettle H: CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC); *J Clin Oncol (ASCO annual meeting proceedings (post-meeting edition) 2008; (vol 26, 20 May Supplement): LBA4504*
- Oettle H, Post S, Neuhaus P et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer; *JAMA* 2007; 17: 267-77
- Picozzi VJ, Abrams RA, Traverso L et al: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon; *J Clin Oncol* 2008 (vol 26, 20 May Supplement): 4505
- Regine WF, Winter KA, Abrams RA et al: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial; *JAMA* 2008; 299(9): 1019
- Seufferlein T, Bachet JB, Van Cutsem E et al.: ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up; *Ann Oncol* 2012; 23(Suppl 7): 33-40
- Van Laethem J, Van Cutsem E, Hammel P, et al: Adjuvant chemotherapy alone versus chemoradiation after curative resection for pancreatic cancer: feasibility results of a randomised EORTC/FFCD/GERCOR phase II/III study (40013/22012/0304); *J Clin Oncol (ASCO annual meeting proceedings (postmeeting edition) 2008; (vol 26, 20 May Supplement): 4514*

- Von Hoff D, Li CP, Wang-Gillam A, et al. Ann Oncol 2014; 25 (Suppl.2): 105-6

## **Pankreaskarzinom – Radio- und/oder Chemotherapie bei lokal fortgeschrittenen Tumoren**

- Ammori JB, Colletti LM, Zalupski MM et al.: Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas; J Gastrointest Surg 2003; 7(6): 766-72
- Brasiuniene B, Juozaityte E: The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer; Medicina (Kaunas) 2007; 43(9): 716
- Breslin TM, Hess KR, Harbison DB et al.: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration; Ann Surg Oncol 2001; 8(2): 123-32
- Chauffert B, Mornex F, Bonnetain F et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer; Definitive results of the 2000–01 FFCD/SFRO study; Ann Oncol 2008; 19(9): 1592–99
- Cohen SJ, Dobelbower R, Lipsitz S et al: A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282; Int J Rad Oncol Biol Phys 2005; 62: 1345-50
- Crane CH, Ellis LM, Abbruzzese JL et al.: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer; J Clin Oncol 2006; 24(7): 1145-51
- Czito BG, Willett CG, Bendell JC et al.: Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results; J Clin Oncol 2006; 24(4): 656-62
- Ducreux M, Cuhna AS, Caramella C et al.: Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up; Ann Oncol 2015; 26(Suppl 5): v56-68
- Fogelman DR, Chen J, Chabot JA et al.: The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX; Surg Oncol Clin N Am 2004; 13(4): 711-35
- Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone; J Natl Cancer Inst 1988; 80(10): 751
- Gillen S, Schuster T, Meyer zum Büschenfelde C: Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages; PLOS 2010 (<http://www.plosmedicine.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pmed.1000267&representation=PDF>)
- Hammel P, Huguet F, Van Laethem JL et al.: Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4

months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study; *J Clin Oncol* 31, 2013 (suppl; abstr LBA4003)

- Hammel P, Hugué F, Van Laethem JL et al.: Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial; *JAMA* 2016; 315(17): 1844-53
- Hazel JJ, Thirlwell MP, Huggins M et al: Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial; *J Can Assoc Radiol* 1981; 32(3): 164
- Hoffman JP, Lipsitz S, Pisansky T et al.: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study; *J Clin Oncol* 1998; 16(1): 317-23
- House MG, Yeo CJ, Cameron JL et al.: Predicting resectability of periampullary cancer with three-dimensional computed tomography; *J Gastrointest Surg* 2004; 8(3): 280-8
- Hugué F, Girard N, Guerche CS et al: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review; *J Clin Oncol* 2009; 27(13): 2269
- Hugué F, Goodman KA, Azria D et al.: Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations; *Int J Radiat Oncol Biol Phys* 2012; 83(5): 1355-64
- Kim HJ, Czischke K, Brennan MF et al.: Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?; *J Gastrointest Surg* 2002; 6(5): 763-9
- Kindler HL, Friberg G, Singh DA et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer; *J Clin Oncol* 2005; 23(31): 8033-40
- Klaassen DJ, MacIntyre JM, Catton GE et al: Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study; *J Clin Oncol* 1985; 3(3): 373
- Koshy MC, Landry JC, Cavanaugh SX et al.: A challenge to the therapeutic nihilism of ESPAC-1; *Int J Radiat Oncol Biol Phys* 2005; 61(4): 965-6
- Krzyzanowska MK, Weeks JC, Earle CC: Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness; *J Clin Oncol*. 2003; 21(18): 3409
- Li CP, Chao Y, Chi KH et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study; *Int J Radiat Oncol Biol Phys* 2003; 57(1): 98
- Loehrer PJ, Powell ME, Cardenes HR et al: A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E420; *J Clin Oncol (ASCO annual meeting proceedings (post-meeting edition))* 2008; 26(20 May Supplement): 4506

- Loehrer PJ Sr, Feng Y, Cardenes H et al: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial; *J Clin Oncol* 2011; 29(31): 4105-12
- Mukherjee S, Hurt CN, Bridgewater J et al: Gemcitabine-based or capecitabinebased chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial; *Lancet Oncol* 2013; 14(4): 317
- Neoptolemos JP, Stocken DD, Friess H et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer; *N Engl J Med* 2004; 350(12): 1200-10
- Petrucciani N, Debs T, Nigri G et al.: Borderline resectable pancreatic cancer: an evolving concept; *Ann Oncol* 2017; 28(9): 2315
- Pipas JM, Barth RJ Jr, Zaki B et al.: Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma; *Ann Surg Oncol* 2005; 12(12): 995-1004
- Quiros RM, Brown KM, Hoffmann JP: Neoadjuvant therapy in pancreatic cancer; *Cancer Invest* 2007; 25(4): 267-73
- Sasson AR, Wetherington RW, Hoffman JP et al.: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome; *Int J Gastrointest Cancer* 2003; 34(2-3): 121-8
- Schneider BJ, Ben-Josef E, McGinn CJ: Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer; *Int J Radiat Oncol Biol Phys* 2005; 63(5): 1325
- Sohn TA, Yeo CJ, Cameron JL et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators; *J Gastrointest Surg* 2000; 4(6): 567-79
- Stokes JB, Nolan NJ, Stelow EB et al: Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer; *Ann Surg Oncol*. 2011; 18(3): 619
- Sultana A, Smith CT, Cunningham D et al.: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer; *J Clin Oncol* 2007; 25(18): 2607-15
- Talamonti MS, Small W Jr, Mulcahy MF et al.: A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma; *Ann Surg Oncol* 2006; 13(2) 150-8
- Tseng JF, Raut CP, Lee JE et al.: Pancreaticoduodenectomy with vascular resection: margin status and survival duration; *J Gastrointest Surg* 2004; 8(8): 935-49 – discussion: 949-50
- Varadhachary GR: Current management of borderline-resectable pancreatic cancer; *Clin Adv Hematol Oncol* 2007; 5(10): 765-7
- Wolff, RA: Initial Results of Preoperative Gemcitabine (GEM)-based Chemoradiation for Resectable Pancreatic Adenocarcinoma; *Proc Am Soc Clin Oncol* 2002; 21: 130a

- Wolff RA, Evans DB, Gravel DM et al.: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma; *Clin Cancer Res* 2001; 7(8): 2246-53
- Xiong HQ, Rosenberg A, LoBuglio A et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer; *J Clin Oncol* 2004; 22: 2610-6

## **Pankreaskarzinom – Palliative Therapie**

- Abou-Alfa GK, Letourneau R, Harker G et al.: A randomized phase III trial of DX- 8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs gemcitabine alone in advanced pancreatic cancer; *Proc Am Soc Clin Oncol* 2004; Abstract 4006
- Berk V, Ozdemir N, Ozkan M et al.: XELOX vs. FOLFOX as second line chemotherapy in advanced pancreatic cancer; *Hepatogastroenterology* 2012; 59(120): 2635-9
- Biswas S, Guix M, Rinehart C et al.: Inhibition of TGF-beta with neutralizing antibodies prevents radiationinduced acceleration of metastatic cancer progression; *J Clin Invest* 2007; 117(5): 1305–13
- Bucher H, Guyatt G, Griffith L et al.: The results of direct and indirect treatment comparisons in meta-analysis of randomised controlled trials; *J Clin Epidemiol* 1997; 50(6): 683–91
- Burris HA 3rd, Moore MJ, Andersen J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial; *J Clin Oncol* 1997; 15(6): 2403-13
- Chiorean EG, Von Hoff DD, Tabernero J et al.: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer; *Br J Cancer* 2016; 115(2): 188-94
- Conroy T, Desseigne F, Ychou M et al. (Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup): FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer; *N Engl J Med* 2011; 364(19): 1817-25
- Corsini MM, Miller RC, Haddock MG et al.: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005); *J Clin Oncol* 2008; 26(21): 3511-6
- Cunningham D, Chau I, Stocken C et al.: Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer; *Eur J Cancer* 2005; 3: 12. Abstract PS11
- Gill S, Ko YJ, Cripps C et al.: PANCREOX: A Randomized Phase III Study of 5-Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy; *J Clin Oncol* 2016; Epub ahead of print
- Glimelius B, Hoffman K, Sjoden PO et al.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer; *Ann Oncol* 1996; 7: 593–600
- Gruen RL, Pitt V, Green S, Parkhill A et al.: The effect of provider case volume on cancer mortality: Systematic review and meta-analysis; *CA Cancer J Clin* 2009; 59: 192-211

- Herman JM, Swartz MJ, Hsu CC et al.: Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital; *J Clin Oncol* 2008; 26(21): 3503-10
- Herrmann R, Bodoky G, Ruhstaller T et al.: Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group; *J Clin Oncol* 2007; 25: 2212-17
- Klinkenbijn JH, Jeekel J, Sahmoud T et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group; *Ann Surg* 1999; 230(6): 776-82
- Kindler HL, Friberg G, Singh DA et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer; *J Clin Oncol* 2005; 23(31): 8033-40
- Kindler HL, Niedzwiecki D, Hollis D et al.: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB); *J Clin Oncol* 2007; ASCO Annual Meeting Proceedings 25 (18S): 4508
- Louvet C, Hincke A, Labianca R et al.: Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): Pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study; *J Clin Oncol* 2006; ASCO Annual Meeting Proceedings 24 (18S): 4003
- Louvet C, Labianca R, Hammel P et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial; *J Clin Oncol* 2005; 23(15): 3509-16
- Moore MJ, Goldstein D, Hamm J et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group; *J Clin Oncol* 2007; 25 (15): 1960-6
- Neoptolemos JP, Dunn JA, Stocken DD, et al: European Study Group for Pancreatic Cancer: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial; *Lancet* 2001; 358(9293): 1576–85
- Neoptolemos JP, Stocken DD, Friess H, et al: European Study Group for Pancreatic Cancer: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer; *New Engl J Med* 2004; 350(12): 1200–10
- Neuhaus P, Riess H, Post S et al: CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC); *J Clin Oncol* (ASCO annual meeting proceedings (post-meeting edition) 2008; (vol 26, 20 May Supplement): LBA4504
- Oettle H, Post S, Neuhaus P et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial; *JAMA* 2007; 297 (3): 267–277

- Oettle H, Riess H, Stieler JM et al.: Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial; *J Clin Oncol* 2014; 32(23): 2423-9
- Philip PA, Benedetti J, Fenoglio-Preiser C et al.: A SWOG phase III study of gemcitabine + cetuximab versus gemcitabine in patients with adenocarcinoma of the pancreas; *J Clin Oncol* 2007; ASCO Annual Meeting Proceedings 25 (18S): 4509
- Poplin E, Levy DE, Berlin J et al.: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201); ASCO 2006, Abstract No: LBA4004
- Regine WF, Winter KW, Abrams R et al.: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial; *JAMA* 2008; 299 (9): 1019–26
- Scheithauer W, Schüll B, Ulrich-Pur H et al.: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial; *Ann Oncol* 2003; 14 (1): 97-104
- Stocken DD, Büchler MW, Dervenis C et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer; *Br J Cancer* 2005; 92 (8): 1372–81
- Sultana A, Tudur Smith C, Cunningham D et al.: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer; *J Clin Oncol* 2007; 25(18): 2607–15
- Sultana A, Tudur Smith C, Cunningham D et al.: Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy; *Br J Cancer* 2007; 96 (8): 1183–90
- Taberero J, Von Hoff D, Moore M et al.: Phase III trial (MPACT) of weekly nabpaclitaxel plus gemcitabine in metastatic pancreatic cancer: influence of prognostic factors on survival; *Ann Oncol* 2013; iv11-iv24 (abstr.0-0001)
- Tempero M, Plunkett W, Ruiz van Haperen V et al.: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed-dose rate infusion in patients with pancreatic adenocarcinoma; *J Clin Oncol* 2003; 21: 3402-8
- Van Heek NT, Kuhlmann KF, Scholten RJ et al.: Hospital volume and mortality after pancreatic resection. A systematic review and an evaluation of intervention in the netherlands; *Annals of Surgery* 2005; 242: 781-90
- Von Hoff DD, Ervin T, Arena FP et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine; *N Engl J Med* 2013; 369(18): 1691-703
- Wang-Gilliam A, Li CP, Bodoky G et al.: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial; *Lancet* 2016; 387(10018): 545-57
- Wilkowski R, Boeck S, Ostermaier S et al.: Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study; *Br J Cancer* 2009; 101(11): 1853-9



- Xiong HQ, Rosenberg A, LoBuglio A et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer; J Clin Oncol 2004; 22: 2610-6
- Yip D, Karapetis C, Strickland A et al.: WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer; Cochrane Database Syst Rev 2009; (4):CD002093. doi: 10.1002/14651858.CD002093.pub3
- Zaniboni A, Aitini E, Barni S et al.: FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicentre phase II study; Cancer Chemother Pharmacol 2012; 69(6): 1641-5

## **Pankresaskarzinom – Leitlinien**

- S3-Leitlinie Exokrines Pankreaskarzinom (gültig Okt 2013-Okt 2018)
- ESMO Clinical Practice Guideline publiziert in Ann Oncol 2015; 26 (suppl 5): v56-68 plus eUpdate vom 20. Juni 2017 mit Empfehlungen für nal-IRI in der Zweitlinie des Pankreaskarzinoms
- ASCO-Guidelines 2016
- NCCN-Guidelines Pancreatic Adenocarcinoma Version 2.2017, April 27, 2017 ([https://www.nccn.org/professionals/physician\\_gls/pdf/pancreatic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf))

## **Neuroendokrine Tumore – Definition, Inzidenz, Klinik, Diagnostik, Chirurgie**

- Birnbaum DJ, Turrini O, Ewald J et al.: Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival; Eur J Surg Oncol 2014; 40(11): 1564-71
- Bosman FT, World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010 pp 417
- Capurso G, Bettini R, Rinzivillo M et al.: Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review; Neuroendocrinology 2011; 93(4): 223-9
- Falconi M, Eriksson B, Kaltsas G et al.: Consensus guidelines update for the management of functional p-NETs (F-p-NETs) and non-functional p-NETs (NF-p-NETs); Neuroendocrinology 2016; 103(2): 153–71
- Fischer L, Bergmann F, Schimmack S et al.: Outcome of surgery for pancreatic neuroendocrine neoplasms; Br J Surg 2014; 101: 1405-12
- Halfdanarson TR, Rubin J, Farnell MB et al.: Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors; Endocrine-Related Cancer 2008; 15: 409-27
- Hashim YM1, Trinkaus KM, Linehan DC et al.: Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs); Ann Surg 2014; 259(2): 197-203
- Kaczirek K, Asari R, Scheuba C et al.: Organic hyperinsulinism and endoscopic surgery; Wien Klin Wochenschr 2005; 117: 19-25
- Klimstra DS, Arnold R, Capella C et al.: In: Bosman F, Carneiro F, Hruban R et al. (eds) (2010) WHO Classification of Tumours of the Digestive System. IARC Press, Lyon pp 322-330

- Klöppel G, Couvelard A, Perren A et al.: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a Standardized Approach to the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors and Their Prognostic Stratification; *Neuroendocrinology* 2009; 90 (2):162–66
- Niederle MB, Hackl M, Kaserer K et al.: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters; *Endocr Relat Cancer* 2010; 17: 909-18
- Niederle MB, Niederle B: Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Tumors: Current Data on a Prospectively Collected, Retrospectively Analyzed Clinical Multicenter Investigation; *Oncologist* 2011; 16: 602-13
- Rindi G, Klöppel G, Alhman H et al.: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system; *Virchows Arch* 2006; 449: 395-401
- Rindi G, Klöppel G, Couvelard A et al.: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system; *Virchows Arch* 2007; 451(4): 757-62
- Rindi G, Arnold R, Bosman FT et al.: In: Bosman F, Carneiro F, Hruban R et al. (eds):WHO Classification of Tumours of the Digestive System; Lyon 2010; IARC Press, pp 13-14
- Rosai J.: Pathology and Genetics of Tumors of the Endocrine Organs. In Kleihues P, Sobin L (editors); Lyon 2017: IARC Press
- Sobin L, Gospodarowicz M, Wittekind C (eds) (2009) UICC: TNM classification of malignant tumours, 7th edition. Wiley-Blackwell, Oxford *Neuroendokrine Tumore – Prognose*
- Strosberg JR, Cheema A, Weber JM et al.: Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications; *Ann Surg* 2012; 256(2): 321-5

## **Neuroendokrine Tumore – Systemische Therapie**

- Caplin ME, Pavel M, Ćwikła JB et al.: Lanreotide in metastatic enteropancreatic neuroendocrine tumors; *N Engl J Med* 2014; 371(3): 224-33
- Cives M, Strosberg J: An update on gastroenteropancreatic neuroendocrine tumors; *Oncology* 2014; 28(9): 749-58
- Jensen RT, Delle Fave G: Promising Advances in the Treatment of Malignant Pancreatic Endocrine Tumors; *NEJM* 2011; 364(6): 564-5
- Raymond E, Dahan L, Raoul JL et al.: Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors; *NEJM* 2011; 364(6): 501-13
- Yao JC, Lombard-Bohas C, Baudin E et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial; *J Clin Oncol* 2010; 28(1): 69-76

- Yao JC, Shah MH, Ito T et al.: for the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors; N Engl J Med 2011; 364(6): 514-23
- Yao JC, Fazio N, Singh S et al.: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study; Lancet 2016; 387(10022): 968-77

## **Neuroendokrine Tumore – Guidelines**

- Pavel M, O'Toole D, Costa F et al: ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site; Neuroendocrinology 2016; 103: 172-85
- Garcia-Carbonero R, Sorbye H, Baudin E et al.: ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas; Neuroendocrinology 2016; 103: 186-94